- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03578198
Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL) (MG4101)
October 24, 2022 updated by: Tae Min Kim, Seoul National University Hospital
Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Phase II study of rituximab plus MG4101 in patients with relapsed or refractory indolent CD20-positive non-Hodgkin lymphoma (NHL) Investigator-Initiated Trials
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of rituximab plus MG4101 in patients with indolent CD20-positive NHLs who has relapsed or refractory to prior chemotherapy or chemo-radiotherapy.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed indolent CD20-positive NHLs (iNHLs; follicular lymphoma grade 1-3a, marginal zone B-cell lymphoma, small lymphocytic lymphoma, Waldenstrom macroglobulinemia)
- CD20-positive iNHL patients who relapsed or progressed
- ≥ 19 years
- ECOG PS 0-2
- At least one bidimensionally measurable disease (or presence of IgM paraproteinemia ≥ 2 x ULN for Waldenstrom macroglobulinemia)
- Adequate hematologic, renal, and hepatic functions
- Appropriate methods of contraception during the study
- Written informed consent
Exclusion Criteria:
- Not all of the above inclusion criteria are met.
- Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks
- Corticosteroids > 10mg/day during last 28 days
- Evidence of CNS involvement by lymphomas
- Active HBV/HCV infections, known HIV infection
- Prior diagnosis of cancers within 5 years
- Serious concurrent cardiovascular disease
- Patients who are pregnant or lactating
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rituximab + MG4101
Drug: Rituximab + MG4101 Induction phase: Rituximab (Truxima) 375mg/m2 IV Weekly (X4) MG4101 3x107 cells/kg IV Weekly (X4) Maintenance phase Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4) MG4101 3x107 cells/kg IV q 4 weeks (X4) |
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: Through treatment completion, an average of 25 weeks
|
Investigator-assessed, confirmed objective response by revised response criteria
|
Through treatment completion, an average of 25 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete remission rate
Time Frame: Through treatment completion, an average of 25 weeks
|
Confirmed complete remission by revised response criteria
|
Through treatment completion, an average of 25 weeks
|
Progression-free survival
Time Frame: From date of initiation until the date of first documented progression, whichever came first, assessed up to 2 years
|
PFS as defined by revised response criteria
|
From date of initiation until the date of first documented progression, whichever came first, assessed up to 2 years
|
Overall survival
Time Frame: Through study completion, an average of 2 years
|
OS as defined by revised response criteria
|
Through study completion, an average of 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Tae Min Kim, MD, PhD, Seoul National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 8, 2018
Primary Completion (Actual)
April 7, 2022
Study Completion (Actual)
April 7, 2022
Study Registration Dates
First Submitted
June 25, 2018
First Submitted That Met QC Criteria
June 25, 2018
First Posted (Actual)
July 6, 2018
Study Record Updates
Last Update Posted (Actual)
October 27, 2022
Last Update Submitted That Met QC Criteria
October 24, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- Truximab+MG4101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CD20-positive Non-Hodgkin Lymphoma
-
Guangzhou Excelmab Inc.RecruitingSafety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin LymphomaCD20-positive Non-Hodgkin LymphomaChina
-
Conjupro Biotherapeutics, Inc.SuspendedCD20 Positive Non Hodgkin LymphomaUnited States
-
Zhejiang Teruisi Pharmaceutical Inc.RecruitingCD20-positive B-cell Non-Hodgkin LymphomaChina
-
Janssen Research & Development, LLCPharmacyclics LLC.CompletedCD20-positive B-cell Non-Hodgkin LymphomaUnited States, France
-
National Cancer Institute (NCI)CompletedRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 PositiveUnited States
-
Beijing Mabworks Biotech Co., Ltd.CompletedCD20-positive B Cell Non-Hodgkin LymphomaChina
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.RecruitingStudy of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's LymphomaCD20-positive B-cell Non-Hodgkin's LymphomaChina
-
Shanghai Pharmaceuticals Holding Co., LtdCompletedCD20 Positive B Cell Non-Hodgkin's LymphomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
-
The First Affiliated Hospital of Soochow UniversityShanghai Unicar-Therapy Bio-medicine Technology Co.,LtdUnknownRefractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | CAR - T CD19/CD20/CD22/CD30China
Clinical Trials on Rituximab + MG4101
-
Samsung Medical CenterCompletedHepatocellular CarcinomaKorea, Republic of
-
Seoul National University HospitalCompleted
-
GC Cell CorporationCompletedHepatocellular CarcinomaKorea, Republic of
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
GC Cell CorporationUnknownRefractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin LymphomaKorea, Republic of
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States